Combining local regional therapy and systemic therapy: Expected changes in the treatment landscape of recurrent hepatocellular carcinoma

Table 1 Clinical studies of systemic therapy in recurrent hepatocellular carcinoma after liver transplantation

Ref.	Medication regimen	Study type	Number of patients	OS (mo)	PFS (mo)	1-yr OS
Iavarone et al[125]	Regorafenib	Retrospective	28	12.9
Li et al[126]	Sorafenib 79%; lenvatinib 2.3%; chemotherapy 4.7%; chemotherapy plus bevacizumab 7.0%; pembrolizumab 2.3%	Retrospective	41	17.0
Li et al[127]	Sorafenib	Retrospective	10	10.0
de'Angelis et al[128]	Sorafenib	Retrospective	15			60%
Gomez-Martin et al[129]	Sorafenib	Retrospective	31	19.3	6.77
Zavaglia et al[130]	Sorafenib	Retrospective	11	5.0
Staufer et al[131]	Sorafenib	Retrospective	13	7.0
López Ortega et al[132]	Sorafenib	Retrospective	17			62%
Weinmann et al[133]	Sorafenib	Retrospective	11	20.1
Piñero et al[134]	Lenvatinib	Case	1	84.0
Sotiropoulos et al[135]	Sorafenib	Retrospective	14	25.0

OS: Overall survival; PFS: Progression-free survival.